We had to use OSGi in a student project for a distributed systems module.
It was a nightmare. We were basically forced to use Eclipse (instead of IntelliJ which everybody was accustomed to). Eclipse alone was a nightmare to use (slow, imports not founds, etc).
On the OSGi side:
There is no package manager. One team tried to set up maven but they failed. We just loaded jars.
The manifest files were a mess. Eclipse launch configurations were a mess (had to be re-imported after any change).
A small project which only required a backend was needlessly split into 5 parts. Over-engineering at its finest.
My take on this: The only thing this will do is make Google either remove the audio captchas or make them super difficult to solve, even for us humans.
Did this but with an app in Germany. As I "scored" 95 out of 100 points and was apparently at the top 1% of the drivers, I got a pretty good discount on my insurance.
About 500€ per year less than without this app. So yeah, for that price they can track me anytime I drive, I don't have an issue with that.
The files are available up until they have been downloaded (from 1 to 100 times) or until a certain timeframe has elapsed (from 5 minutes to 7 days). See the screenshot at the article.
I travel quite a bit on the weekends, on the way to my girlfriend, and all toilets that I've seen are nfc-enabled (Baden-Württemberg -- Bayern). Except for Crailsheim. There are Toilets by the Bahn, but are closed at 18:00 or so.
> Until data from well-designed clinical trials are available and reliable, and standardized CBD products that are produced using GMP are available, caution must be exercised in any consideration of using CBD for the treatment of epilepsy. In the meantime, based upon promising preliminary data, further clinical research should be wholeheartedly pursued.
Citing a part of the second paper's Conclusion:
> Human experimental findings support preclinical findings, and also suggest a lack of anxiogenic effects, minimal sedative effects, and an excellent safety profile. Current preclinical and human findings mostly involve acute CBD dosing in healthy subjects, so further studies are required to establish whether chronic dosing of CBD has similar effects in relevant clinical populations. Overall, this review emphasizes the potential value and need for further study of CBD in the treatment of anxiety disorders.
So the second one says it seems good for acute dosing. Both say more research has to be done. Let's hope this is being done in the near future.
